Tetrathiomolybdate vs Trientine Therapy in Wilson Disease

This study focuses on treating patients with Wilson Disease, a condition where excess copper accumulates in the body. The main goal is to compare the effectiveness of two different treatments: tetrathiomolybdate (TM) and trientine. The study is important because it could help improve the care for patients with Wilson Disease by identifying which treatment works better and is safer. The study is designed for patients with this condition. In this double-blind, randomized study, patients are assigned to one of two treatment arms. In the first arm, patients receive TM three times a day with meals and three times a day between meals for 8 weeks. In the second arm, patients receive trientine therapy for 8 weeks. Patients in the TM group may also receive maintenance zinc, while those in the trientine group may continue on trientine or switch to zinc. The study measures the results by evaluating the patients' response to these treatments over the 8-week period.